Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Treatment-Refractory Major Depressive Disorder
NCT02122562Phase 2Recruiting
- Start
- Apr 2014
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD). Started Apr 2014; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02122562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122562.